MSCIS suitable for phacolytic glaucoma patients

Article

Manual small incision cataract surgery (MSCIS) with trypan blue staining of the anterior capsule is a safe and effective method of cataract extraction for patients with phacolytic glaucoma.

Manual small incision cataract surgery (MSCIS) with trypan blue staining of the anterior capsule is a safe and effective method of cataract extraction for patients with phacolytic glaucoma, according to a report published in the March issue of the British Journal of Ophthalmology.

Rengaraj Venkatesh and colleagues from the Aravind Eye Hospital, India and the Eye Institute at Tan Tock Seng Hospital, Singapore, conducted a non-randomized interventional case series of three patients with phacolytic glaucoma undergoing cataract extraction by MSICS, with trypan blue staining of the anterior capsule.

The mean preoperative intraocular pressure (IOP) was 46.2 mmHg. In 31 patients, an intraocular lens (IOL) was implanted in the posterior chamber and in the further two subjects, the posterior capsule was removed leaving aphakia due to severe pre-existing zonulysis. Postoperative best corrected visual acuity (BCVA) was 20/60 or better in 29 patients and 20/40 or better in 26 patients. In all 33 cases, the IOP was 22 mmHg or less without the use of anti-glaucoma medications (mean IOP was 15.1 mmHg). Postoperative corneal oedema occurred in 11 cases and anterior chamber inflammation was noted in nine cases. Both were resolved with standard medical therapy.

The authors of the study concluded that MSCIS with trypan blue staining is a safe and effective method of extracting cataracts in patients with phacolytic glaucoma.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.